Polysialic Acid Modified Liposomes for Improving Pharmacokinetics and Overcoming Accelerated Blood Clearance Phenomenon
Source abstract
Abstract
Poly (ethylene glycol) (PEG) modified nanocarriers are being used widely in the drug delivery system (DDS). However, the “accelerated blood clearance (ABC) phenomenon” was induced upon repeated administration of PEG-modified liposomes, resulting in reduced blood circulation time, and increased accumulation in liver and spleen. To avoid the unexpected phenomenon, polysialic acid (PSA) was selected to modify liposomes. PSA is a natural, highly hydrophilic polysaccharide polymer for which no receptors exists in the body. It is non-immunogenic, biodegradable and endows the conjugated bioactive macromolecule and drugs with increased circulation time in vivo. In the present study, the in vivo evaluation showed that PSA modified liposomes (PSA-Lip) afford extended blood circulation in wistar rats and beagle dogs. Moreover, the ABC phenomenon did not occur and the IgM antibody was not induced after repeated injections of PSA-Lip. These results strongly suggest that PSA modification represents a promising strategy to afford good stealth of the liposomes without evoking the ABC phenomenon.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
Funding
National Natural Science Foundation of China
References (54)
Show source-provided references
1. PEGylation of nanocarrier drug delivery systems: State of the art10.1166/jbn.2008.021 ↗
2. PEGylation: A promising strategy to overcome challenges to cancer-targeted nanomedicines: A review of challenges to clinical transition and promising resolution10.1007/s13346-019-00631-4 ↗
3. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo10.1016/0005-2736(91)90246-5 ↗
4. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery10.1007/s11095-007-9284-6 ↗
5. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives10.1002/anie.200902672 ↗
6. Liposomal drug delivery systems: From concept to clinical applications10.1016/j.addr.2012.09.037 ↗
7. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery10.1016/j.jconrel.2013.11.016 ↗
8. PH-induced destabilization of phosphatidylethanolamine-containing liposomes: Role of bilayer contact10.1021/bi00302a029 ↗
9. Liposome clearance10.1023/A:1020134521778 ↗
10. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review10.1016/S0168-3659(99)00248-5 ↗
11. Polyethylene glycol functionalized gold nanoparticles: The influence of capping density on stability in various media10.1007/s13404-011-0015-8 ↗
12. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics10.1002/jps.21278 ↗
13. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
14. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes
15. PEGylated liposomes: Immunological responses10.1080/14686996.2019.1627174 ↗
16. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin10.1016/j.ijpharm.2014.09.047 ↗
17. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: Roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions10.1021/acsnano.9b03942 ↗
18. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice10.1016/j.jconrel.2003.12.011 ↗
19. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes10.1016/j.jconrel.2005.04.003 ↗
20. Polysialic acids: Potential in improving the stability and pharmacokinetics of proteins and other therapeutics10.1007/PL00000676 ↗
21. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics10.1016/S0378-5173(01)00603-2 ↗
22. Cell biology of polysialic acid10.1016/S0959-4388(97)80083-9 ↗
23. Role of charge and hydration in effects of polysialic acid on molecular interactions on and between cell membranes10.1016/S0021-9258(17)31616-2 ↗
24. Polysialic acid: Three-dimensional structure, biosynthesis and function10.1016/S0959-440X(98)80144-9 ↗
25. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae10.1084/jem.187.5.743 ↗
26. Structural and mechanistic analysis of sialic acid synthase NeuB from Neisseria meningitidis in complex with Mn2+, phosphoenolpyruvate, and N-acetylmannosaminitol10.1074/jbc.M411942200 ↗
27. Polysialic acid: Overcoming the hurdles of drug delivery10.4155/tde.13.153 ↗
28. Development of a nattokinase-polysialic acid complex for advanced tumor treatment10.1016/j.ejps.2020.105241 ↗
29. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency10.1007/s13346-018-0496-6 ↗
30. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity10.1016/j.ijpharm.2018.06.021 ↗
31. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation10.1016/j.ijpharm.2016.10.051 ↗
32. Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., and Altman, D.G. (2010). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol., 8.10.1371/journal.pbio.1000412 ↗
33. Preparation of alendronate liposomes for enhanced stability and bioactivity: In vitro and in vivo characterization10.1208/s12248-008-9060-5 ↗
34. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis10.1016/j.ejps.2013.09.013 ↗
35. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome10.1016/S0378-5173(02)00075-3 ↗
36. Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes10.3109/10611869509015957 ↗
37. Polysialic acid as a drug carrier: Evaluation of a new polysialic acid-epirubicin conjugate and its comparison against established drug carriers10.1039/C2PY20876H ↗
38. Polysialylated insulin: Synthesis, characterization and biological activity in vivo10.1016/S0304-4165(03)00116-8 ↗
39. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats10.1016/j.ejps.2011.11.014 ↗
40. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: A new challenge for sequential low-dose chemotherapy
41. A noticeable phenomenon: Thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats10.1016/j.ejpb.2013.10.002 ↗
42. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes10.1016/j.biomaterials.2010.02.049 ↗
43. A frustrating problem: Accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats10.1016/j.ejpb.2012.04.023 ↗
44. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles10.1007/s11095-009-9943-x ↗
45. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles
46. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs10.1016/j.ijpharm.2012.07.049 ↗
47. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes10.1016/j.jconrel.2006.01.005 ↗
48. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes10.1016/j.jconrel.2007.02.010 ↗
49. Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: A comparison with purified B polysaccharide10.1128/iai.47.2.527-533.1985 ↗
50. Membrane oligo- and polysialic acids10.1016/j.bbamem.2011.08.036 ↗
51. Disialic, oligosialic and polysialic acids: Distribution, functions and related disease10.1093/jb/mvt057 ↗
52. Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs
53. Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon10.1007/s13346-018-0588-3 ↗
54. Accelerated blood clearance of nanoemulsions modified with PEG-cholesterol and PEG-phospholipid derivatives in rats: The effect of PEG-lipid linkages and PEG molecular Weights10.1021/acs.molpharmaceut.9b00770 ↗